The subjects in the study by Brouwer et al. were exposed to a much lower cumulative dose of MTX compared to our subjects [15]. Bower et al., in contrast to the above-mentioned studies, disclosed that MTX therapy in gestational trophoblastic tumors hastened menopause by three years on an average [16]. In a study involving systemic lupus erythematosus subjects [17], there was a significant inverse correlation between AMH levels and cumulative dose of MTX, parallel to our findings. This evidence concerns the gene AMH and trophoblastic neoplasm.